Literature DB >> 23580570

Single copies of mutant KRAS and mutant PIK3CA cooperate in immortalized human epithelial cells to induce tumor formation.

Grace M Wang1, Hong Yuen Wong, Hiroyuki Konishi, Brian G Blair, Abde M Abukhdeir, John P Gustin, D Marc Rosen, Samuel Ray Denmeade, Zeshaan Rasheed, William Matsui, Joseph P Garay, Morassa Mohseni, Michaela J Higgins, Justin Cidado, Danijela Jelovac, Sarah Croessmann, Rory L Cochran, Sivasundaram Karnan, Yuko Konishi, Akinobu Ota, Yoshitaka Hosokawa, Pedram Argani, Josh Lauring, Ben Ho Park.   

Abstract

The selective pressures leading to cancers with mutations in both KRAS and PIK3CA are unclear. Here, we show that somatic cell knockin of both KRAS G12V and oncogenic PIK3CA mutations in human breast epithelial cells results in cooperative activation of the phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways in vitro, and leads to tumor formation in immunocompromised mice. Xenografts from double-knockin cells retain single copies of mutant KRAS and PIK3CA, suggesting that tumor formation does not require increased copy number of either oncogene, and these results were also observed in human colorectal cancer specimens. Mechanistically, the cooperativity between mutant KRAS and PIK3CA is mediated in part by Ras/p110α binding, as inactivating point mutations within the Ras-binding domain of PIK3CA significantly abates pathway signaling. In addition, Pdk1 activation of the downstream effector p90RSK is also increased by the combined presence of mutant KRAS and PIK3CA. These results provide new insights into mutant KRAS function and its role in carcinogenesis. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23580570      PMCID: PMC3674106          DOI: 10.1158/0008-5472.CAN-12-1578

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  39 in total

1.  Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.

Authors:  Wendy De Roock; Derek J Jonker; Federica Di Nicolantonio; Andrea Sartore-Bianchi; Dongsheng Tu; Salvatore Siena; Simona Lamba; Sabrina Arena; Milo Frattini; Hubert Piessevaux; Eric Van Cutsem; Chris J O'Callaghan; Shirin Khambata-Ford; John R Zalcberg; John Simes; Christos S Karapetis; Alberto Bardelli; Sabine Tejpar
Journal:  JAMA       Date:  2010-10-27       Impact factor: 56.272

2.  Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells.

Authors:  B Elenbaas; L Spirio; F Koerner; M D Fleming; D B Zimonjic; J L Donaher; N C Popescu; W C Hahn; R A Weinberg
Journal:  Genes Dev       Date:  2001-01-01       Impact factor: 11.361

3.  Deletion of p53 in human mammary epithelial cells causes chromosomal instability and altered therapeutic response.

Authors:  M B Weiss; M I Vitolo; M Mohseni; D M Rosen; S R Denmeade; B H Park; D J Weber; K E Bachman
Journal:  Oncogene       Date:  2010-06-21       Impact factor: 9.867

4.  PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.

Authors:  Ensar Halilovic; Qing-Bai She; Qing Ye; Raymond Pagliarini; William R Sellers; David B Solit; Neal Rosen
Journal:  Cancer Res       Date:  2010-08-10       Impact factor: 12.701

5.  Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus.

Authors:  Federica Di Nicolantonio; Sabrina Arena; Josep Tabernero; Stefano Grosso; Francesca Molinari; Teresa Macarulla; Mariangela Russo; Carlotta Cancelliere; Davide Zecchin; Luca Mazzucchelli; Takehiko Sasazuki; Senji Shirasawa; Massimo Geuna; Milo Frattini; José Baselga; Margherita Gallicchio; Stefano Biffo; Alberto Bardelli
Journal:  J Clin Invest       Date:  2010-07-26       Impact factor: 14.808

6.  Delineating genetic alterations for tumor progression in the MCF10A series of breast cancer cell lines.

Authors:  Mitsutaka Kadota; Howard H Yang; Bianca Gomez; Misako Sato; Robert J Clifford; Daoud Meerzaman; Barbara K Dunn; Lalage M Wakefield; Maxwell P Lee
Journal:  PLoS One       Date:  2010-02-15       Impact factor: 3.240

7.  Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations.

Authors:  J Lauring; D P Cosgrove; S Fontana; J P Gustin; H Konishi; A M Abukhdeir; J P Garay; M Mohseni; G M Wang; M J Higgins; D Gorkin; M Reis; B Vogelstein; K Polyak; M Cowherd; P J Buckhaults; B H Park
Journal:  Oncogene       Date:  2010-01-25       Impact factor: 9.867

8.  Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1.

Authors:  Ayaz Najafov; Eeva M Sommer; Jeffrey M Axten; M Phillip Deyoung; Dario R Alessi
Journal:  Biochem J       Date:  2011-01-15       Impact factor: 3.857

9.  Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis.

Authors:  Alyssa L Kennedy; Jennifer P Morton; Indrani Manoharan; David M Nelson; Nigel B Jamieson; Jeff S Pawlikowski; Tony McBryan; Brendan Doyle; Colin McKay; Karin A Oien; Greg H Enders; Rugang Zhang; Owen J Sansom; Peter D Adams
Journal:  Mol Cell       Date:  2011-04-08       Impact factor: 17.970

10.  Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer.

Authors:  Stefan Eser; Nina Reiff; Marlena Messer; Barbara Seidler; Kathleen Gottschalk; Melanie Dobler; Maren Hieber; Andreas Arbeiter; Sabine Klein; Bo Kong; Christoph W Michalski; Anna Melissa Schlitter; Irene Esposito; Alexander J Kind; Lena Rad; Angelika E Schnieke; Manuela Baccarini; Dario R Alessi; Roland Rad; Roland M Schmid; Günter Schneider; Dieter Saur
Journal:  Cancer Cell       Date:  2013-02-28       Impact factor: 31.743

View more
  25 in total

1.  A phosphoproteomic screen demonstrates differential dependence on HER3 for MAP kinase pathway activation by distinct PIK3CA mutations.

Authors:  Brian G Blair; Xinyan Wu; Muhammad Saddiq Zahari; Morassa Mohseni; Justin Cidado; Hong Yuen Wong; Julia A Beaver; Rory L Cochran; Daniel J Zabransky; Sarah Croessmann; David Chu; Patricia Valda Toro; Karen Cravero; Akhilesh Pandey; Ben Ho Park
Journal:  Proteomics       Date:  2014-12-28       Impact factor: 3.984

Review 2.  Emerging role of the KRAS-PDK1 axis in pancreatic cancer.

Authors:  Riccardo Ferro; Marco Falasca
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

3.  PIK3CA mutations and TP53 alterations cooperate to increase cancerous phenotypes and tumor heterogeneity.

Authors:  Sarah Croessmann; Hong Yuen Wong; Daniel J Zabransky; David Chu; D Marc Rosen; Justin Cidado; Rory L Cochran; W Brian Dalton; Bracha Erlanger; Karen Cravero; Berry Button; Kelly Kyker-Snowman; Paula J Hurley; Josh Lauring; Ben Ho Park
Journal:  Breast Cancer Res Treat       Date:  2017-02-11       Impact factor: 4.872

4.  The butterfly effect in cancer: a single base mutation can remodel the cell.

Authors:  Jonathan R Hart; Yaoyang Zhang; Lujian Liao; Lynn Ueno; Lisa Du; Marloes Jonkers; John R Yates; Peter K Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-12       Impact factor: 11.205

5.  Somatic loss of PIK3R1 may sensitize breast cancer to inhibitors of the MAPK pathway.

Authors:  Sanja B Turturro; Matthew S Najor; Timothy Yung; Liam Portt; Christopher S Malarkey; Abde M Abukhdeir; Melody A Cobleigh
Journal:  Breast Cancer Res Treat       Date:  2019-06-17       Impact factor: 4.872

6.  Engineering PTEN function: membrane association and activity.

Authors:  Jr-Ming Yang; Hoai-Nghia Nguyen; Hiromi Sesaki; Peter N Devreotes; Miho Iijima
Journal:  Methods       Date:  2014-10-22       Impact factor: 3.608

7.  Hotspot SF3B1 mutations induce metabolic reprogramming and vulnerability to serine deprivation.

Authors:  W Brian Dalton; Eric Helmenstine; Noel Walsh; Lukasz P Gondek; Dhanashree S Kelkar; Abigail Read; Rachael Natrajan; Eric S Christenson; Barbara Roman; Samarjit Das; Liang Zhao; Robert D Leone; Daniel Shinn; Taylor Groginski; Anil K Madugundu; Arun Patil; Daniel J Zabransky; Arielle Medford; Justin Lee; Alex J Cole; Marc Rosen; Maya Thakar; Alexander Ambinder; Joshua Donaldson; Amy E DeZern; Karen Cravero; David Chu; Rafael Madero-Marroquin; Akhilesh Pandey; Paula J Hurley; Josh Lauring; Ben Ho Park
Journal:  J Clin Invest       Date:  2019-08-08       Impact factor: 14.808

8.  Engineering ePTEN, an enhanced PTEN with increased tumor suppressor activities.

Authors:  Hoai-Nghia Nguyen; Jr-Ming Yang; Yashar Afkari; Ben Ho Park; Hiromi Sesaki; Peter N Devreotes; Miho Iijima
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-16       Impact factor: 11.205

9.  HER2 missense mutations have distinct effects on oncogenic signaling and migration.

Authors:  Daniel J Zabransky; Christopher L Yankaskas; Rory L Cochran; Hong Yuen Wong; Sarah Croessmann; David Chu; Shyam M Kavuri; Monica Red Brewer; D Marc Rosen; W Brian Dalton; Ashley Cimino-Mathews; Karen Cravero; Berry Button; Kelly Kyker-Snowman; Justin Cidado; Bracha Erlanger; Heather A Parsons; Kristen M Manto; Ron Bose; Josh Lauring; Carlos L Arteaga; Konstantinos Konstantopoulos; Ben Ho Park
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-27       Impact factor: 11.205

10.  TrkA overexpression in non-tumorigenic human breast cell lines confers oncogenic and metastatic properties.

Authors:  Kelly Kyker-Snowman; Robert M Hughes; Christopher L Yankaskas; Karen Cravero; Swathi Karthikeyan; Berry Button; Ian Waters; David Marc Rosen; Lauren Dennison; Natasha Hunter; Josh Donaldson; Eric S Christenson; Konstantinos Konstantopoulos; Paula J Hurley; Sarah Croessmann; Ben Ho Park
Journal:  Breast Cancer Res Treat       Date:  2019-12-10       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.